Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Completed No phase listed Observational

A Study to Assess Choroideremia (CHM) Health Outcomes

NCT04750785
View directory record Official record
Conditions
Choroideremia
Interventions
No Intervention
Other
Lead sponsor
Biogen
Industry
Eligibility
Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

NCT00048737
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Zevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide, Allogeneic Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 17, 2026, 1:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Felzartamab, Tacrolimus, Standard of Care IST
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
16
States / cities
Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

NCT00412412
View directory record Official record
Conditions
Breast Cancer
Interventions
CNF2024, CNF2024 + trastuzumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Tampa, Florida • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

NCT02071121
View directory record Official record
Conditions
Healthy
Interventions
BIIB061, Placebo, 14C-BIIB061
Drug
Lead sponsor
Biogen
Industry
Eligibility
20 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

NCT01538472
View directory record Official record
Conditions
Lymphoma
Interventions
Y Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, Stem Cell Infusion, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 17, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

NCT02881567
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
Daclizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Tampa, Florida • Des Moines, Iowa • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

NCT06640933
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 58 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glymphatic Kinetics In Healthy Adult Volunteers

NCT03218111
View directory record Official record
Conditions
Healthy
Interventions
MR Imaging, CT-guidance
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 17, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
dimethyl fumarate, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • San Francisco, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

NCT05005338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

NCT03496012
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

NCT02106897
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy Volunteers
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

Assessing Tolerability of Avonex Intramuscular Injections

NCT01641120
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935
View directory record Official record
Conditions
Ocular Cicatricial Pemphigoid
Interventions
Rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

NCT02128113
View directory record Official record
Conditions
Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Interventions
Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
Felzartamab, Placebo
Drug · Other
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BIIB014 Cardiovascular Monitoring Study

NCT01035515
View directory record Official record
Conditions
Healthy
Interventions
Placebo, BIIB014 50mg, BIIB014 100mg
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 17, 2026, 1:05 AM EDT
Terminated Phase 1 Interventional

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

NCT00319930
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
CNF1010 (17-AAG)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Ocoee, Florida • Albany, New York • Dayton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 17, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

NCT04079101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB104, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 17, 2026, 1:05 AM EDT